RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated his 'Outperform' rating on IDEAYA Biosciences (NASDAQ:IDYA), maintaining a price target of $32.
October 11, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEAYA Biosciences' stock may see positive movement as RBC Capital maintains its 'Outperform' rating and $32 price target.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, RBC Capital's reiteration of an 'Outperform' rating and a $32 price target for IDEAYA Biosciences indicates a positive outlook for the company's stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100